Clinical trials: Raltitrexed
Head and Neck Squamous Cell Carcinoma
Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.
The purpose of this study is to evaluate the efficacy of radiotherapy combine with raltitrexed in older patients with head and neck squamous cell carcinoma.
- Trial name
- NCT03196843
- Testing
- Raltitrexed, Intensity Modulated Radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma
This is a single-arm clinical trial.The purpose of this study is to evaluate the efficacy and safety of Raltitrexed and Paclitaxel as second-line chemotherapy for patients with unresectable or metastatic gastric or…
- Trial name
- NCT03083613
- Testing
- Raltitrexed, Paclitaxel
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer.
- Trial name
- NCT06823050
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Xuhua Duan
Colon Cancer Liver Metastasis
Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases
The purpose of this study was a randomized controlled trial to compare the effect of oxaliplatin and raltitrexed treatment of colorectal cancer with liver metastases by TACE hepatic artery infusion
- Trial name
- NCT02557490
- Testing
- oxaliplatin and raltitrexed
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhu Xu
Advanced Gastric Cancer
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy in Paclitaxel plus raltitrexed plug compare with taxol second-line treatment for advanced gastric cancer
- Trial name
- NCT02072317
- Testing
- taxel plus raltitrexed, taxol
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Colorectal Cancer
RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)
Raltitrexed is an inhibitor of thymidylate synthase.As a folate antimetabolite drug, raltitrexed has been used in treatment of colorectal cancer(CRC) since 1998, and also used in malignant mesothelioma.Several phase III studies…
- Trial name
- NCT03813641
- Testing
- Raltitrexed, Capecitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen People's Hospital
Advanced Colorectal Cancer
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer
- Trial name
- NCT03126071
- Testing
- Raltitrexed, Irinotecan, Oxaliplatin
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Raltitrexed in Treating Children With Refractory Acute Leukemia
Phase I trial to study the effectiveness of raltitrexed in treating children with refractory acute leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
- Trial name
- NCT00003528
- Testing
- raltitrexed
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan…
- Trial name
- NCT06118762
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Gastric Cancer
Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
The purpose of this study is to determine whether raltitrexed concurrent with IMRT is safe, tolerable and effective in the treatment for patients with local-advanced gastric cancer after D0/D1 radical resection.
- Trial name
- NCT03392103
- Testing
- Raltitrexed, postoperative radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhongnan Hospital
Regorafenib, Raltitrexed
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.
- Conditions
- Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment
- Trial name
- NCT05426811
- Testing
- Regorafenib, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- China Medical University, China
Rectal Neoplasms
Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
Neoadjuvant chemoradiation (CRT), is considered the standard treatment of locally advanced rectal cancer with a positive impact on locoregional control and survival.However, patients with T4 rectal cancer show high risk of local…
- Trial name
- NCT02723253
- Testing
- Radiotherapy, Tom-OX
- Volunteers
- 18 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Inoperable Esophageal Cancer Stage I-III
A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer
The aim of this study was to compare raltitrexed/oxaliplatin plus radiotherapy versus radiotherapy in subjects with inoperable esophageal cancer.
- Trial name
- NCT01732380
- Testing
- Raltitrexed, Oxaliplatin, Radiotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- The First People's Hospital of Lianyungang
Gastric Cancer
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line…
- Trial name
- NCT01836120
- Testing
- Raltitrexed plus Docetaxel, Docetaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Tumor Hospital
Cholangioadenoma
RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.
- Trial name
- RALOXBTC (NCT05148143)
- Testing
- Raltitrexed combined with oxaplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Inoperable or Recurrent Rectal Cancer
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response rate and increasing the resectability of…
- Trial name
- TOMUDEX (NCT00590278)
- Testing
- Tomudex, Radiotherapy, Haematology
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Metastatic Colon Cancer
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
- Trial name
- NCT02618356
- Testing
- Raltitrexed and S-1
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Malignant Mesothelioma
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of raltitrexed in treating patients who have malignant…
- Trial name
- NCT00004254
- Testing
- raltitrexed
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colorectal Cancer
Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
Raltitrexed is a potent thymidylate synthase (TS) inhibitor. Conversely to 5-fluorouracil (5FU), raltitrexed can be administered safely in patients with cardiovascular disease, as well as in patients with dihydropyrimidine…
- Trial name
- EROS (NCT02821559)
- Testing
- TOMOX, Bevacizumab
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon